PD-1 Inhibition to Determine CNS Reservoir of HIV-Infection

Trial Profile

PD-1 Inhibition to Determine CNS Reservoir of HIV-Infection

Phase of Trial: Phase I

Latest Information Update: 15 Dec 2017

At a glance

  • Drugs Pembrolizumab (Primary)
  • Indications Adenocarcinoma; Bladder cancer; Bone cancer; Brain metastases; Breast cancer; Chronic lymphocytic leukaemia; Colorectal cancer; Diffuse large B cell lymphoma; Endometrial cancer; Fallopian tube cancer; Follicular lymphoma; Gastric cancer; Gastrointestinal cancer; Germ cell and embryonal neoplasms; Glioblastoma; Glioma; Haematological malignancies; Head and neck cancer; Hepatocellular carcinoma; Hodgkin's disease; Human papillomavirus infections; Inflammatory breast cancer; Liver cancer; Malignant melanoma; Merkel cell carcinoma; Mesothelioma; Multiple myeloma; Nasopharyngeal cancer; Non-Hodgkin's lymphoma; Non-small cell lung cancer; Oesophageal cancer; Osteosarcoma; Ovarian cancer; Pancreatic cancer; Penile cancer; Peritoneal cancer; Prostate cancer; Rectal cancer; Recurrent respiratory papillomatosis; Renal cell carcinoma; Small cell lung cancer; Soft tissue sarcoma; Solid tumours; Squamous cell cancer; Thymoma; Thyroid cancer; Urogenital cancer
  • Focus Adverse reactions; Proof of concept
  • Most Recent Events

    • 14 Dec 2017 Planned initiation date changed from 30 nov to 19 Dec 2017.
    • 24 Nov 2017 Planned initiation date changed from 2 Nov 2017 to 30 Nov 2017.
    • 26 Oct 2017 Planned initiation date changed from 31 Oct 2017 to 1 Nov 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top